Tocilizumab prescribing criteria for COVID-19 patients

Ayman M. Al-Qaaneha Clinical Pharmacy Services Division, Pharmacy Services Department, Johns Hopkins Aramco Healthcare (JHAH), Dhahran, Saudi Arabia;b Institute for Research and Medical Consultations (IRMC), Imam Abdulrahman Bin Faisal University, Dammam, Saudi ArabiaCorrespondence[email protected]

https://orcid.org/0000-0002-6342-6573

Fuad H. Al-Ghamdia Clinical Pharmacy Services Division, Pharmacy Services Department, Johns Hopkins Aramco Healthcare (JHAH), Dhahran, Saudi Arabia

References

Hu B, Huang S, Yin L. The cytokine storm and COVID-19. J Med Virol. 2020 [2020 June 28]. doi:10.1002/jmv.26232.
Web of Science ®Google Scholar
Ye Q, Wang B, Mao J. The pathogenesis and treatment of the `Cytokine Storm‘ in COVID-19. J Infect. 2020 [2020 April 14];80(6):607–13. doi:10.1016/j.jinf.2020.03.037.
PubMed Web of Science ®Google Scholar
Meftahi G, Jangravi Z, Sahraei H, Bahari Z. The possible pathophysiology mechanism of cytokine storm in elderly adults with COVID-19 infection: the contribution of “inflame-aging”. Inflamm Res. 2020 [2020 June 13]:1–15. doi:10.1007/s00011-020-01372-8.
PubMed Web of Science ®Google Scholar
Lakatos B, Gopcsa L, Gondos E, Riczu A, Várnai Z, Nagy É, Molnár E, Bekő G, Bobek I, Reményi P, et al. [Anti-cytokine therapy in novel coronavirus disease (COVID-19) – the first administration of TTocilizumab in Hungary at a department of infectology]. Orv Hetil. 2020 [2020 June 17];161:1070–77. doi:10.1556/650.2020.31899.
PubMed Web of Science ®Google Scholar
Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: A single center experience. J Med Virol. 2020 [2020 April 8];92(7):814–18. doi:10.1002/jmv.25801.
PubMed Web of Science ®Google Scholar
Alzghari SK, Acuña VS. Supportive treatment with tocilizumab for COVID-19: a systematic review. J Clin Virol. 2020 [2020 May 1];127:104380. doi:10.1016/j.jcv.2020.104380.
PubMed Web of Science ®Google Scholar
Toniati P, Piva S, Cattalini M, Garrafa E, Regola F, Castelli F, Franceschini F, Airò P, Bazzani C, Beindorf E-A, et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. Autoimmun Rev. 2020;19(7):102568. doi:10.1016/j.autrev.2020.102568.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Tocilizumab prescribing criteria for COVID-19 patients

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Tocilizumab prescribing criteria for COVID-19 patients

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date